Osteoradionecrosis in cancer patients: the evidence base for treatment-dependent frequency, current management strategies, and future studies
- 1.2k Downloads
The purpose of this study is to review the evidence base from 1990 to 2008 to (1) clarify the impact of cancer therapies on prevalence of osteoradionecrosis (ORN) in head and neck cancer patients, and to (2) evaluate management strategies and their consequences on quality of life and cost of care.
Articles were selected for the time period beginning after 1989, excluding the 1990 NCI monograph articles from the 1989 NIH-sponsored Oral Complications in Cancer Therapy Symposium that was published in 1990. The search included both Medline/PubMed and Embase and was limited to humans. The search was limited to publications in the English language. No abstracts were utilized in the current review. Each article was evaluated by two reviewers. A weighted prevalence was calculated for the prevalence of ORN while incorporating predetermined quality measures. The level of evidence, recommendation grade, and guideline (if possible) were provided for published preventive and management strategies for ORN.
A total of 43 articles between 1990 and 2008 were reviewed. The weighted prevalence for ORN included conventional radiotherapy (RT) = 7.4%, intensity modulated RT (IMRT) = 5.1%, chemoradiotherapy (CRT) = 6.8%, and brachytherapy = 5.3%. Hyperbaric oxygen may contribute a role in management of ORN. However, no clear guideline recommendations could be established for the prevention or treatment of ORN based on the literature reviewed.
New cancer treatment modalities such as IMRT and concomitant CRT have had minimal effect on prevalence of ORN. No studies to date have systematically addressed impact of ORN on either quality of life or cost of care.
KeywordsOsteoradionecrosis Head and neck radiation Cancer
The authors thank Ms. Tainika Williams, Department of Oral Medicine, Carolinas Medical Center, North Carolina, USA, for her excellent administrative assistance.
Conflicts of interest
The authors declared that they have no potential conflicts of interests.
- 3.National Institutes of Health (1990) Consensus development conference on oral complications of cancer therapies: diagnosis, prevention, and treatment. Bethesda, Maryland, April 17–19, 1989. NCI Monogr 9:1–184Google Scholar
- 4.National Institutes of Health (2009) Oral complications of emerging cancer therapies. Bethesda, MD USA, April 14-15, 2009 (Primary funding provided by National Institutes of Health, Bethesda, MD, USA)Google Scholar
- 5.Brennan MT, Elting LS, Spijkervet FK (2010) Systematic reviews of oral complications from cancer therapies, Oral Care Study Group, MASCC/ISOO: methodology and quality of the literature. Supp Care Cancer. doi: 10.1007/s00520-010-0856-3
- 6.Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(9 Suppl):1995–2025CrossRefPubMedGoogle Scholar
- 8.Efron B (1993) An introduction to the bootstrap. Chapman and Hall, New York CityGoogle Scholar
- 14.Marx RE, Johnson RP (1988) Problem wounds in oral and maxillofacial surgery: the role of hyperbaric oxygenation. In: Davis JC, Hunt TK (eds) Problem wounds-the role of oxygen. Elsevier, New York, pp 65–128Google Scholar
- 31.Grabenbauer GG, Rodel C, Brunner T, Schulze-Mosgau S, Strnad V, Muller RG, Iro H, Sauer R (2001) Interstitial brachytherapy with Ir-192 low-dose-rate in the treatment of primary and recurrent cancer of the oral cavity and oropharynx. Review of 318 patients treated between 1985 and 1997. Strahlenther Onkol 177:338–344CrossRefPubMedGoogle Scholar
- 33.Abitbol A, Abdel-Wahab M, Lewin A, Troner M, Rodrigues MA, Hamilton-Nelson KL, Markoe A (2002) Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol. Int J Radiat Oncol Biol Phys 53:942–947PubMedGoogle Scholar
- 39.Withers HR, Peters LJ, Taylor JM, Owen JB, Morrison WH, Schultheiss TE, Keane T, O’Sullivan B, van Dyk J, Gupta N et al (1995) Late normal tissue sequelae from radiation therapy for carcinoma of the tonsil: patterns of fractionation study of radiobiology. Int J Radiat Oncol Biol Phys 33:563–568PubMedGoogle Scholar
- 44.Arias F, Dominguez MA, Illarramendi JJ, Martinez E, Tejedor M, Dominguez S, Duenas M, Villafranca E, Elcarte F, Miqueliz S et al (1995) Split hyperfractionated accelerated radiation therapy and concomitant cisplatin for locally advanced head and neck carcinomas: a preliminary report. Int J Radiat Oncol Biol Phys 33:675–682PubMedGoogle Scholar
- 50.Maguire PD, Meyerson MB, Neal CR, Hamann MS, Bost AL, Anagnost JW, Ungaro PC, Pollock HD, McMurray JE, Wilson EP, Kotwall CA (2004) Toxic cure: hyperfractionated radiotherapy with concurrent cisplatin and fluorouracil for stage III and IVA head-and-neck cancer in the community. Int J Radiat Oncol Biol Phys 58:698–704PubMedGoogle Scholar